LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide.
The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele fractions ≥0.01%, are associated with increased relapse and worse overall survival.3 Recent studies show emerging evidence that pre-transplant MRD testing for NPM1 and FLT3-ITD identifies AML patients in remission who are most likely to relapse or experience poor survival.3,4,5
With this approval, LabPMM is helping to transform the landscape of AML research, treatment and drug development. By using MRD as a surrogate endpoint in clinical trials, instead of relying solely on overall survival (OS), pharmaceutical companies can accelerate their drug development timelines. This is particularly valuable in acute disease, where time is of the essence, and earlier intervention can dramatically improve patient outcomes.
“We are proud to receive New York State approval for our NPM1 MRD Assay by NGS, marking our second assay approved by New York State this year,” said Jordan Thornes, V.P., Global Clinical Laboratory Operations at LabPMM. “This milestone reflects our continued dedication to advancing precision diagnostics in cancer care. With this latest approval, we’re further empowering clinicians with sensitive, reliable tools to detect residual disease and guide treatment decisions with confidence.”
LabPMM’s NPM1 and FLT3 ITD MRD Assays are standardized next generation sequencing (NGS) tests that complement the LeukoStrat® CDx FLT3 Mutation Assay, which is used to guide treatment selection for patients with AML. These services are offered in the U.S., European Union, and across Asia to ensure patients around the world have access to high-quality, standardized testing and to support the development of cutting-edge cancer treatments. LabPMM remains committed to advancing precision medicine and improving outcomes for patients worldwide. For more information about the NPM1 MRD Assay and LabPMM’s full test menu, please visit https://invivoscribe.com/clinical-lab-services/ or contact us at inquiry@invivoscribe.com and follow us on LinkedIn.
About Invivoscribe
Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.
- Falini, B. et al. Blood. 2020; 136(15):1707–1721.
- Kelemen, K. Life. 2022; 12(1): 109.
- Dillon, L. et al. JAMA. 2023; 329(9):745-755
- Dillon, L. et al. JAMA Oncology. 2024; 10(8)1104-1110
- Levis, M. et al. Blood. 2025; 145(19):2138-2148.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617961412/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UBS Invests in UK Fintech Icon Solutions to Shape the Future of Payments Technology18.6.2025 10:49:00 CEST | Press release
Swiss bank leads new funding round; joined by existing investors Citi and NatWest Icon Solutions, the UK fintech enabling banks globally to design and implement state-of-the-art payment systems, has today announced a new equity investment from UBS. Icon has also secured additional funding from existing investors Citi and NatWest. Pieter Brouwer, Head of Group Operations and Technology Office (GOTO) for Personal & Corporate Banking and GWM Switzerland & International, at UBS comments: “Icon, an important partner of UBS, plays a crucial role in modernizing payment platforms with innovative infrastructure solutions.” Brouwer adds: “This investment reinforces our partnership with Icon and confirms our commitment to deliver faster to market, future-ready payment solutions for our clients. The collaboration helps us drive innovation at scale and enhances our capabilities for seamless instant payments and advanced transaction processing.” UBS will join existing investors Citi and NatWest – wh
SINOVAC Announces New Board Member18.6.2025 10:38:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the “Board”) and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang’s resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Board to fill the vacancy created by such resignation under the laws of Antigua and Barbuda. Mr. Hsu has also been elected as a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board. Mr. Hsu is a General Partner and Portfolio Manager at Or
StrongPoint Launches RetailQ: Data-Driven Analytics Service for Grocery E-Commerce Fulfillment18.6.2025 10:00:00 CEST | Press release
StrongPoint, the grocery technology company, today announced the launch of RetailQ, an analytics service designed to help grocery retailers uncover real cost savings in their order picking operations. RetailQ is ananalytics service that uses advanced digital simulation and virtual pick bots to help grocery retailers identify cost savings and improve efficiency in their in-store picking operations. By digitally modelling every step of the fulfillment process, RetailQ enables retailers to test different scenarios, quantify the impact of operational changes, optimize workflows and reveal hidden inefficiencies. Grocery retailers can leverage the RetailQ service to: Uncover hidden inefficiencies such as underutilized pick paths or staffing imbalances Benchmark performance and leverage best practices Assess service standards, out-of-stock occurrences, and product substitutions Identify operational bottlenecks, both now and in the future Identify and eliminate non-value-adding tasks in the wo
Ohmium International Appoints Veteran Energy Sector Leader as New CEO to Accelerate Global Growth and Scale18.6.2025 09:59:00 CEST | Press release
Ohmium International, a leading manufacturer of advanced PEM hydrogen electrolyzers, announced the appointment of Dr. Markus Tacke as its new CEO, effective July 1, 2025. With over 22 years of experience at Siemens and a proven track record in the renewable energy sector, Dr. Tacke will drive Ohmium's global expansion and commercialization of its next-generation green hydrogen solutions. Dr. Tacke has a history of growing companies in energy, infrastructure, manufacturing, and technology. His focus on customer centricity, operational efficiency, and strategic acquisitions has consistently driven growth and value. As CEO of Oerlikon Surface Solutions AG, he achieved 8% annual growth and turned the company from break-even to 9% profitability through regional integration and new business exploration. At Siemens Gamesa Renewable Energy, he streamlined product lines, launched advanced platforms, and initiated a €2.5 billion cost savings program, stabilizing the wind business and launching a
Americhem Aligns European Region Under Global Brand18.6.2025 09:00:00 CEST | Press release
Americhem Inc., a global leader in polymer solutions, has unified its European operations under the Americhem brand—streamlining customer experience and reinforcing alignment across global quality and manufacturing standards. “This move simplifies how we scale and serve,” said CEO John Richard. “One brand delivers clarity, consistency, and confidence.” The Denmark site supports Americhem’s healthcare strategy, producing ISO 13485 compounds for hearing aids, surgical tools, and drug delivery. Clean compounding developed in North America has been replicated, with expansion planned in Asia. Key focus areas also include fibers and building products, where material durability, color precision, and speed-to-market matter most. Local teams now operate fully within Americhem’s global systems. “Customers here get the same responsiveness and quality trusted across our global network,” said Barto DuPlessis, Vice President and General Manager of Europe. The shift also advances Americhem’s 2030 sus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom